Athira Pharma Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Athira Pharma Receives Nasdaq Non-Compliance Notice
U.S. RESEARCH ROUNDUP-Athira pharma, Lowe's Companies, P&G
U.S. RESEARCH ROUNDUP- Autozone, Costco Wholesale, Walmart
U.S. STOCKS ON THE MOVE-Asana, Ascendis Pharma, oil firms
U.S. STOCKS ON THE MOVE-Trade Desk, Nasdaq, RingCentral
U.S. STOCKS ON THE MOVE-PagerDuty, AMD, Athira Pharma
U.S. STOCKS ON THE MOVE-Nvidia, Zscaler, Dollar Tree
Athira Pharma tumbles after Alzheimer's drug fails trial
U.S. RESEARCH ROUNDUP-Array Technologies, Hess, Lennar
Athira Pharma falls as Alzheimer's drug fails in mid-to-late stage trial
Brief: Athira Pharma Announces Topline Results From Phase 2/3 Lift-Ad Clinical Trial
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial (updated)
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial
U.S. RESEARCH ROUNDUP-Apple, Centerpoint Energy, Cummins
Brief: Athira Pharma Q2 Operating Expenses USD 28.028 Million
Brief: Athira Announces Last Patient Completed LIFT-AD Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Brief: Athira Pharma Announces Proposed Settlement Of Stockholder Derivative Action
Athira Pharma Inc reports results for the quarter ended in March - Earnings Summary